FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2604554544> ?p ?o ?g. }

• W2604554544 endingPage "121" @default.
• W2604554544 startingPage "113" @default.
• W2604554544 abstract "Infection with human cytomegalovirus (HCMV) is a serious medical problem, particularly in immunocompromised individuals and neonates. The success of (val)ganciclovir therapy is hampered by low drug compatibility and induction of viral resistance. A novel strategy of antiviral treatment is based on the exploitation of cell-directed signaling, e. g. pathways with a known relevance for carcinogenesis and tumor drug development. Here we describe a principle for putative antiviral drugs based on targeting dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs). DYRKs constitute an evolutionarily conserved family of protein kinases with key roles in the control of cell proliferation and differentiation. Members of the DYRK family are capable of phosphorylating a number of substrate proteins, including regulators of the cell cycle, e.g. DYRK1B can induce cell cycle arrest, a critical step for the regulation of HCMV replication. Here we provide first evidence for a critical role of DYRKs during viral replication and the high antiviral potential of DYRK inhibitors (SC84227, SC97202 and SC97208, Harmine and AZ-191). Using established replication assays for laboratory and clinically relevant strains of HCMV, concentration-dependent profiles of inhibition were obtained. Mean inhibitory concentrations (EC50) of 0.98 ± 0.08 μM/SC84227, 0.60 ± 0.02 μM/SC97202, 6.26 ± 1.64 μM/SC97208, 0.71 ± 0.019 μM/Harmine and 0.63 ± 0.23 μM/AZ-191 were determined with HCMV strain AD169-GFP for the infection of primary human fibroblasts. A first analysis of the mode of antiviral action suggested a block of viral replication at the early-late stage of HCMV gene expression. Moreover, rhesus macaque cytomegalovirus (RhCMV), varicella-zoster virus (VZV) and herpes simplex virus (HSV-1) showed a similarly high sensitivity to these compounds. Thus, we conclude that DYRK signaling represents a promising target pathway for the development of novel anti-herpesviral strategies." @default.
• W2604554544 created "2017-04-14" @default.
• W2604554544 creator A5008704671 @default.
• W2604554544 creator A5031400021 @default.
• W2604554544 creator A5031660301 @default.
• W2604554544 creator A5040106299 @default.
• W2604554544 creator A5040808433 @default.
• W2604554544 creator A5043335832 @default.
• W2604554544 creator A5052002848 @default.
• W2604554544 creator A5052738316 @default.
• W2604554544 creator A5052967645 @default.
• W2604554544 creator A5054113590 @default.
• W2604554544 creator A5057324599 @default.
• W2604554544 creator A5068515964 @default.
• W2604554544 creator A5079421880 @default.
• W2604554544 creator A5084325387 @default.
• W2604554544 creator A5089773178 @default.
• W2604554544 date "2017-07-01" @default.
• W2604554544 modified "2023-10-17" @default.
• W2604554544 title "Inhibitors of dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) exert a strong anti-herpesviral activity" @default.
• W2604554544 cites W147693856 @default.
• W2604554544 cites W1605728736 @default.
• W2604554544 cites W1957658076 @default.
• W2604554544 cites W1963630960 @default.
• W2604554544 cites W1966672378 @default.
• W2604554544 cites W1971378307 @default.
• W2604554544 cites W1974484718 @default.
• W2604554544 cites W1975058616 @default.
• W2604554544 cites W1980439069 @default.
• W2604554544 cites W1980518192 @default.
• W2604554544 cites W1989015543 @default.
• W2604554544 cites W1989444544 @default.
• W2604554544 cites W1991575826 @default.
• W2604554544 cites W1992288932 @default.
• W2604554544 cites W1994051530 @default.
• W2604554544 cites W2007123668 @default.
• W2604554544 cites W2033020094 @default.
• W2604554544 cites W2036707789 @default.
• W2604554544 cites W2038809002 @default.
• W2604554544 cites W2044936417 @default.
• W2604554544 cites W2046433603 @default.
• W2604554544 cites W2047619953 @default.
• W2604554544 cites W2056952591 @default.
• W2604554544 cites W2069870015 @default.
• W2604554544 cites W2077185287 @default.
• W2604554544 cites W2078353937 @default.
• W2604554544 cites W2086683597 @default.
• W2604554544 cites W2105047045 @default.
• W2604554544 cites W2113427515 @default.
• W2604554544 cites W2115445238 @default.
• W2604554544 cites W2118279792 @default.
• W2604554544 cites W2123344591 @default.
• W2604554544 cites W2124716540 @default.
• W2604554544 cites W2127260871 @default.
• W2604554544 cites W2127648663 @default.
• W2604554544 cites W2137952286 @default.
• W2604554544 cites W2140976458 @default.
• W2604554544 cites W2151981672 @default.
• W2604554544 cites W2152535908 @default.
• W2604554544 cites W2152705959 @default.
• W2604554544 cites W2153868064 @default.
• W2604554544 cites W2156733385 @default.
• W2604554544 cites W2158973497 @default.
• W2604554544 cites W2165903332 @default.
• W2604554544 cites W2169067144 @default.
• W2604554544 cites W2170308653 @default.
• W2604554544 cites W2174645876 @default.
• W2604554544 cites W2319680233 @default.
• W2604554544 cites W2347056806 @default.
• W2604554544 cites W2513288174 @default.
• W2604554544 cites W2516064313 @default.
• W2604554544 cites W2544089963 @default.
• W2604554544 doi "https://doi.org/10.1016/j.antiviral.2017.04.003" @default.
• W2604554544 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28400201" @default.
• W2604554544 hasPublicationYear "2017" @default.
• W2604554544 type Work @default.
• W2604554544 sameAs 2604554544 @default.
• W2604554544 citedByCount "25" @default.
• W2604554544 countsByYear W26045545442018 @default.
• W2604554544 countsByYear W26045545442019 @default.
• W2604554544 countsByYear W26045545442020 @default.
• W2604554544 countsByYear W26045545442021 @default.
• W2604554544 countsByYear W26045545442022 @default.
• W2604554544 countsByYear W26045545442023 @default.
• W2604554544 crossrefType "journal-article" @default.
• W2604554544 hasAuthorship W2604554544A5008704671 @default.
• W2604554544 hasAuthorship W2604554544A5031400021 @default.
• W2604554544 hasAuthorship W2604554544A5031660301 @default.
• W2604554544 hasAuthorship W2604554544A5040106299 @default.
• W2604554544 hasAuthorship W2604554544A5040808433 @default.
• W2604554544 hasAuthorship W2604554544A5043335832 @default.
• W2604554544 hasAuthorship W2604554544A5052002848 @default.
• W2604554544 hasAuthorship W2604554544A5052738316 @default.
• W2604554544 hasAuthorship W2604554544A5052967645 @default.
• W2604554544 hasAuthorship W2604554544A5054113590 @default.
• W2604554544 hasAuthorship W2604554544A5057324599 @default.
• W2604554544 hasAuthorship W2604554544A5068515964 @default.
• W2604554544 hasAuthorship W2604554544A5079421880 @default.

• next